DiaSorin partners with MeMed to develop and commercialize diagnostics solution
Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections
Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections
Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method
Rapid increase in production of VTM and saline will help boost virus testing
The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses
Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions
Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
The AI-Rad Companion Brain MR and Prostate MR measures volumetric changes in brain, and segments prostate for targeted biopsy under MRI and ultrasound fusion imaging respectively
The Somatom scanner is equipped with a forward-looking camera and motorized wheels, allowing a single technologist to navigate the device through hospital hallways
Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies
Join us on Tuesday, September 1, to learn about why patients are admitted to an intensive care unit and what is available in terms of physiological support, monitoring, and treatments
Learn about the potential of lateral flow assays in detecting symptomatic and asymptomatic COVID-19 infections
The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings
Trial supports Abbott's focus on being the best partner for electrophysiologists treating people living with atrial fibrillation
Exclusive interviews, new methods, free downloads, and much more to help you advance your work
87 percent of patients in ZUMA-2 pivotal trial responded to single infusion of Tecartus
The study is the first global, randomized, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting
The ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 is a probe-based reverse transcription PCR test